PRGO (Perrigo) Forward P/S Multiple

Corporate emblem and logo of Perrigo Company plc (PRGO)

The over-the-counter market is characterized by aggressive dumping, which is confirmed by the change in the projected P/S for Perrigo Company plc (PRGO). The value of 0.60 corresponds to the current metric, reflecting pressure from competition with private labels and raw material issues. Additionally, profitability is impacted by restructuring challenges in pediatric nutrition and potential batch recalls, although a resilient core portfolio mitigates the decline in demand.

PRGO Perrigo: Forward Price to Sales in the range 07/04/2022 - 11/13/2026

Analytical breakdowns for Perrigo Company plc

- market price and analyst price targets:
Basic company analysis:PRGO (Perrigo)
Product sample of Perrigo Corp

The restructuring of Perrigo Company plc (PRGO) and its focus on high-margin consumer brands make the analysis of sales efficiency critically important. This indicator compares the current market value of the business with expected annual sales volume, allowing for an assessment of the asset's overbought status. Monitoring the projected price-to-sales ratio helps identify the risk of a correction in a timely manner if forecasted revenue targets are not met.

Competitor analysis

Price-to-Projected Revenue Ratio Haleon HLN|KVUE (Kenvue Inc) - Future Price to Revenue|Verona Pharma Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Jyong Bio|Ligand Pharmaceuticals (LGND) - Price-to-Projected Revenue Ratio|amneal.com - Forward Price to Sales|Price-to-Projected Revenue Ratio Alvotech SA|LQDA: Forward Price to Sales|Forward P/S Multiple GLPG|Market Cap to Expected Sales Ratio ANI Pharmaceuticals Corp|Forward P/S Multiple MNKD (MannKind Corporation)|Projected Price to Revenue amphastar.com|PCRX - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio ARS Pharmaceuticals Inc|TBPH (Theravance) - Forward Price-to-Revenue Multiple|Aquestive Corp - Forward Price to Sales|SCPH (scPharmaceuticals, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Tectonic (TECX)|Price-to-Projected Revenue Ratio Tonix Pharmaceuticals Holding Corp. (TNXP)|SXTC - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Eupraxia Pharmaceuticals Inc. EPRX|BHST - Forward Price-to-Revenue Multiple|EXOZ - Price-to-Projected Revenue Ratio|Future Price to Revenue ORMP|ENTX: Forward P/S Multiple|MindWalk Holdings, Inc. (HYFT) - Forward P/S Multiple|Price-to-Projected Revenue Ratio ABVC BioPharma Inc|Market Cap to Projected Revenue CPIX (Cumberland Corp)|Forward Price-to-Revenue Multiple QNTM (Quantum BioPharma Ltd)|FGEN - Market Cap to Future Revenue Ratio|Telomir Pharmaceuticals, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales RANI|SNYR - Price-to-Projected Revenue Ratio|Future Price to Revenue RLYB|lexariabioscience.com (LEXX) - Price-to-Projected Revenue Ratio|PULM (pulmatrix.com) - Price-to-Projected Revenue Ratio|PTHL (Pheton Holdings Limited) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Aptorum (APM)|Price-to-Projected Revenue Ratio Lyra Therapeutics, Inc (LYRA)|IBO: Future Price to Revenue|Price-to-Projected Revenue Ratio TNF Pharmaceuticals, Inc. TNFA|Forward Price to Sales YCBD|PainReform - Forward P/S Multiple|Projected Price to Revenue Altamira Therapeutics (CYTO)|Lipella (LIPO) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio OptiNose Corp (OPTN)|Price-to-Projected Revenue Ratio Pieris Pharmaceuticals|procapsgroup.com - Future Price to Revenue|Forward P/S Multiple PTPI|QLI (Qilian International Holding Group) - Forward Price to Sales|Forward P/S Multiple SLRN (ACELYRIN, Inc.)|Forward P/S Multiple TFF Pharmaceuticals, Inc TFFP